Walter S Marcantoni1, Bertine Sandra Akoumba2, Maggy Wassef2, Julie Mayrand2, Hinatea Lai2, Stéphane Richard-Devantoy3, Sylvie Beauchamp4. 1. CIUSSS du l'Ouest-de-l'Île-de-Montréal (Quebec), Canada; Concordia University (Quebec), Canada. Electronic address: walter.marcantoni.comtl@ssss.gouv.qc.ca. 2. CIUSSS du l'Ouest-de-l'Île-de-Montréal (Quebec), Canada. 3. McGill University (Quebec), Canada; Douglas Mental Health University Institute (Quebec), Canada. 4. CIUSSS du l'Ouest-de-l'Île-de-Montréal (Quebec), Canada; McGill University (Quebec), Canada.
Abstract
BACKGROUND: Sub-anaesthetic administration of ketamine is an emerging practice in patients presenting treatment resistant depression (TRD), however several outstanding questions have yet to be answered. OBJECTIVE: To evaluate the effect of intravenous ketamine infusion for patients presenting TRD on depression scores, clinical remission and response rates, and to assess its efficacy over both time and frequency. METHODS: Five databases were searched up to January 4th 2019 to include primary studies evaluating the use of sub-anaesthetic dose of ketamine in adults presenting TRD. Two reviewers independently performed the study selection, quality assessment and data extraction. Results were summarised in a narrative synthesis. A meta-analysis using a random effects model was performed when possible to examine changes in standardized mean differences and odds ratios of outcome measures at 4 hours, 24 hours, or 7 days post-infusion. RESULTS: Twenty-eight studies in 35 publications were included. A strong ketamine effect was observed within 4 hours following a single infusion, and peaked at 24 hours. Ketamine's effectiveness was still present, yet somewhat diminished, 7 days post-infusion. Multiple infusions resulted in an enhanced and prolonged ketamine effect. LIMITS: Due to insufficient data, long-term safety and efficacy of ketamine utilisation in patients presenting TRD are yet to be investigated. CONCLUSIONS: Results provide support for the use of ketamine in the rapid management of depressive symptoms. While ketamine appears promising in the short-term treatment of TRD, more clinical and experimental data is needed with regards to the efficacy, tolerance and security of long-term administration of ketamine.
BACKGROUND: Sub-anaesthetic administration of ketamine is an emerging practice in patients presenting treatment resistant depression (TRD), however several outstanding questions have yet to be answered. OBJECTIVE: To evaluate the effect of intravenous ketamine infusion for patients presenting TRD on depression scores, clinical remission and response rates, and to assess its efficacy over both time and frequency. METHODS: Five databases were searched up to January 4th 2019 to include primary studies evaluating the use of sub-anaesthetic dose of ketamine in adults presenting TRD. Two reviewers independently performed the study selection, quality assessment and data extraction. Results were summarised in a narrative synthesis. A meta-analysis using a random effects model was performed when possible to examine changes in standardized mean differences and odds ratios of outcome measures at 4 hours, 24 hours, or 7 days post-infusion. RESULTS: Twenty-eight studies in 35 publications were included. A strong ketamine effect was observed within 4 hours following a single infusion, and peaked at 24 hours. Ketamine's effectiveness was still present, yet somewhat diminished, 7 days post-infusion. Multiple infusions resulted in an enhanced and prolonged ketamine effect. LIMITS: Due to insufficient data, long-term safety and efficacy of ketamine utilisation in patients presenting TRD are yet to be investigated. CONCLUSIONS: Results provide support for the use of ketamine in the rapid management of depressive symptoms. While ketamine appears promising in the short-term treatment of TRD, more clinical and experimental data is needed with regards to the efficacy, tolerance and security of long-term administration of ketamine.
Authors: Rebecca B Price; Nicholas Kissel; Andrew Baumeister; Rebecca Rohac; Mary L Woody; Elizabeth D Ballard; Carlos A Zarate; William Deakin; Chadi G Abdallah; Adriana Feder; Dennis S Charney; Michael F Grunebaum; J John Mann; Sanjay J Mathew; Bronagh Gallagher; Declan M McLoughlin; James W Murrough; Suresh Muthukumaraswamy; Rebecca McMillan; Rachael Sumner; George Papakostas; Maurizio Fava; Rebecca Hock; Jennifer L Phillips; Pierre Blier; Paulo Shiroma; Peter Šóš; Tung-Ping Su; Mu-Hong Chen; Mikael Tiger; Johan Lundberg; Samuel T Wilkinson; Meredith L Wallace Journal: Mol Psychiatry Date: 2022-09-07 Impact factor: 13.437
Authors: Miguel Pérez de la Mora; Dasiel O Borroto-Escuela; Minerva Crespo-Ramírez; José Del Carmen Rejón-Orantes; Daniel Alejandro Palacios-Lagunas; Magda K Martínez-Mata; Daniela Sánchez-Luna; Emiliano Tesoro-Cruz; Kjell Fuxe Journal: Cells Date: 2022-06-02 Impact factor: 7.666
Authors: Eric P McMullen; Yena Lee; Orly Lipsitz; Leanna M W Lui; Maj Vinberg; Roger Ho; Nelson B Rodrigues; Joshua D Rosenblat; Bing Cao; Hartej Gill; Kayla M Teopiz; Danielle S Cha; Roger S McIntyre Journal: Adv Ther Date: 2021-04-30 Impact factor: 3.845
Authors: Bronagh Gallagher; Meabh Foley; Claire M Slattery; Gabriele Gusciute; Enda Shanahan; Declan M McLoughlin Journal: HRB Open Res Date: 2022-01-27